Weiming Xia, PhD
Professor, Pharmacology, Physiology & Biophysics
Biography
Dr. Xia completed his graduate studies at the University of Texas Medical School at Houston where he earned his MS and PhD degrees (Biochemistry and Molecular Biology). He completed his postdoctoral training in Alzheimer’s disease (AD) at Brigham and Women’s Hospital, Harvard Medical School. In 1999 he became Assistant Professor of Neurology at Harvard Medical School and established a NIH-funded research lab to study AD. In 2012 he joined Department of Veterans Affairs Bedford VA Medical Center, and he leads an independent lab to explore molecular mechanism and biomarkers for AD.
Dr. Xia’s research interests involve target identification, characterization, validation and early stage drug development, with exploration of clinical biomarkers for AD. He has established multiple platforms to quantify pathological proteins like amyloid ß protein (Aß), Tau, neuroinflammatory factors, and related biomarkers. He also develops Mass Spectrometry-based analytic approaches to explore biomarkers for AD and other central nervous system disorders.
Other Positions
- Bedford VA - Edith Nourse Rogers Memorial VA Hosp
Education
- University of Texas Health Science Center at Houston, PhD
- University of Texas Health Science Center at Houston, MS
- Fudan University, BS
Publications
- Published on 9/25/2023
Aguilar BJ, Miller D, Jasuja G, Li X, Shishova E, O'Connor MK, Nguyen A, Morin P, Berlowitz D, Zhang R, Monfared AAT, Zhang Q, Xia W. Rule-Based Identification of Individuals with Mild Cognitive Impairment or Alzheimer's Disease Using Clinical Notes from the United States Veterans Affairs Healthcare System. Neurol Ther. 2023 Dec; 12(6):2067-2078. PMID: 37747662.
Read at: PubMed - Published on 5/11/2023
Chung J, Sahelijo N, Maruyama T, Hu J, Panitch R, Xia W, Mez J, Stein TD, Saykin AJ, Takeyama H, Farrer LA, Crane PK, Nho K, Jun GR. Alzheimer's disease heterogeneity explained by polygenic risk scores derived from brain transcriptomic profiles. Alzheimers Dement. 2023 Nov; 19(11):5173-5184. PMID: 37166019.
Read at: PubMed - Published on 3/18/2023
Morin PJ, Zhang Q, Xia W, Miller D, Querfurth H, Tahami Monfared AA. Clinical and Scientific Challenges to Effectiveness Studies Under Coverage with Evidence Development in Alzheimer's Disease. Neurol Ther. 2023 Jun; 12(3):721-726. PMID: 36933140.
Read at: PubMed - Published on 1/20/2023
Kirsch D, Shah A, Dixon E, Kelley H, Cherry JD, Xia W, Daley S, Aytan N, Cormier K, Kubilus C, Mathias R, Alvarez VE, Huber BR, McKee AC, Stein TD. Vascular injury is associated with repetitive head impacts and tau pathology in chronic traumatic encephalopathy. J Neuropathol Exp Neurol. 2023 Jan 20; 82(2):127-139. PMID: 36617181.
Read at: PubMed - Published on 1/1/2023
Vig V, Garg I, Tuz-Zahra F, Xu J, Tripodis Y, Nicks R, Xia W, Alvarez VE, Alosco ML, Stein TD, Subramanian ML. Vitreous Humor Biomarkers Reflect Pathological Changes in the Brain for Alzheimer's Disease and Chronic Traumatic Encephalopathy. J Alzheimers Dis. 2023; 93(3):1181-1193. PMID: 37182888.
Read at: PubMed - Published on 12/31/2022
Prasad M, Xu J, Agranat JS, Xia W, Daley S, Ness S, Chen X, Siegel NH, Stein TD, Chung J, Subramanian ML. Upregulation of Neuroinflammatory Protein Biomarkers in Acute Rhegmatogenous Retinal Detachments. Life (Basel). 2022 Dec 31; 13(1). PMID: 36676067.
Read at: PubMed - Published on 7/1/2022
Morin P, Li M, Wang Y, Aguilar BJ, Berlowitz D, Tahami Monfared AA, Irizarry M, Zhang Q, Xia W. Clinical Staging of Alzheimer's Disease: Concordance of Subjective and Objective Assessments in the Veteran's Affairs Healthcare System. Neurol Ther. 2022 Sep; 11(3):1341-1352. PMID: 35778542.
Read at: PubMed - Published on 2/9/2022
Turk KW, Geada A, Alvarez VE, Xia W, Cherry JD, Nicks R, Meng G, Daley S, Tripodis Y, Huber BR, Budson AE, Dwyer B, Kowall NW, Cantu RC, Goldstein LE, Katz DI, Stern RA, Alosco ML, Mez J, McKee AC, Stein TD. A comparison between tau and amyloid-ß cerebrospinal fluid biomarkers in chronic traumatic encephalopathy and Alzheimer disease. Alzheimers Res Ther. 2022 02 09; 14(1):28. PMID: 35139894.
Read at: PubMed - Published on 2/9/2022
Panitch R, Hu J, Xia W, Bennett DA, Stein TD, Farrer LA, Jun GR. Blood and brain transcriptome analysis reveals APOE genotype-mediated and immune-related pathways involved in Alzheimer disease. Alzheimers Res Ther. 2022 02 09; 14(1):30. PMID: 35139885.
Read at: PubMed - Published on 2/9/2022
Jun GR, You Y, Zhu C, Meng G, Chung J, Panitch R, Hu J, Xia W, Bennett DA, Foroud TM, Wang LS, Haines JL, Mayeux R, Pericak-Vance MA, Schellenberg GD, Au R, Lunetta KL, Ikezu T, Stein TD, Farrer LA. Protein phosphatase 2A and complement component 4 are linked to the protective effect of APOE ?2 for Alzheimer's disease. Alzheimers Dement. 2022 Nov; 18(11):2042-2054. PMID: 35142023.
Read at: PubMed
View 116 more publications: View full profile at BUMC